Loading clinical trials...
Loading clinical trials...
CATAMARAN - Neonatal Cohort : Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
Congenital heart defects (CHD), as the leading cause of birth defects, affect 12 million people globally and approximately 41,000 newborns each year in Europe. CHD presents a significant public health concern due to its association with high morbidity and mortality rates across the lifespan. Over 50% of infants born with critical CHD will develop neurodevelopmental disorders (NDD), requiring specialized care and impacting their quality of life. NDDs, involving early and persistent disruptions in cognitive, emotional, and behavioral development due to abnormal brain development, are highly variable. They may impact language, learning, motor skills, intellectual efficiency, social cognition, attention, memory, and executive functions, often accompanied by psychosocial difficulties. These hidden disabilities constitute the primary long-term sequelae of CHD, surpassing even cardiovascular complications in impact, and affect children who often undergo multiple cardiac surgeries during early childhood. NDDs are associated not only with complex CHDs but also with simpler CHDs that are repaired in early childhood and considered 'cured.' The origin of CHD-associated NDDs remains largely unknown. While few genetic or environmental causes have been identified, recent research suggests a possible common origin linking heart malformations and neurodevelopmental abnormalities. The CATAMARAN neonatal cohort project aims to detect developmental delays associated with CHD as early as six months of age and to identify both individual susceptibility factors and acquired vulnerabilities contributing to the development of NDDs in infants with CHD.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Nantes University Hospital
Nantes, Loire Atlantique, France
CHU de Bordeaux
Bordeaux, France
APHP - Antoine Béclère
Clamart, France
Hôpital Marie Lannelongue
Le Plessis-Robinson, France
AP-HM
Marseille, France
AP-HP Necker
Paris, France
CHU de Toulouse
Toulouse, France
CHRU Tours
Tours, France
Start Date
February 28, 2025
Primary Completion Date
August 28, 2027
Completion Date
August 28, 2027
Last Updated
March 20, 2026
450
ESTIMATED participants
Neurodevelopmental assessment (Bayley-IV)
BEHAVIORAL
Biological sampling
OTHER
ELFE dietary questionnaire
BEHAVIORAL
Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)
BEHAVIORAL
Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)
OTHER
Lead Sponsor
Nantes University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions